All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
To help navigate the exciting content being presented at the EHA2021 Virtual Congress, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in multiple myeloma and amyloid light-chain (AL) amyloidosis.
EHA2021 abstracts: What’s hot in multiple myeloma and AL amyloidosis?
If you would like to view the top abstracts to look out for in MM at EHA 2021, please download the resource below.Download here
The interim analysis results of the phase III IKEMA trial | Isatuximab + Kd for the treatment of relapsed and refractory multiple myeloma
Philippe Moreau, Steering Committee member of the MM Hub, and colleagues reported the results of Isa + Kd in...
Why daratumumab + VRd + cyclophosphamide might be an option to consider for high-risk NDMM?
During the 2021 ASCO Annual Meeting and the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Martin Kaiser, The Institute of Cancer Research,...
Subscribe to get the best content related to multiple myeloma delivered to your inbox